Abstract
Perioperative Chemotherapy (PCT) is considered the standard treatment for locally advanced gastroesophageal cancer (GEC) since the 2006 MAGIC trial (Cunningham et al.) reported a 5-year overall survival (OS) of 36% in PCT patients and 23% for surgery (SG) alone. 89% of the enrolled patients were <70 years, 21% were aged 70+. In Europe and the US many population-based cancer registries (CRs) gather data on treatment, which can be used to assess care patterns at population level and evaluate the reproducibility of clinical trial results in the real world.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
